Navigation Links
Induced Pluripotent Stem Cells Combo Could Yield Much-needed Models to Study Vascular Disease
Date:6/19/2017

A study recently published in STEM CELLS Translational Medicine shows smooth muscle and vascular endothelial cells induced from pluripotent stem cells perform similarly to their naturally evolving counterparts under conditions that mimic hardening of the arteries and other blood vessel diseases. The finding opens the door to modeling rare vascular diseases necessary for research, as well as assists in screening new drugs and developing personalized cell-based therapies.

Researchers have difficulty studying vascular diseases – those affecting the blood vessels – because of a scarcity of human tissue samples and difficulty in accurately modeling the disease of interest. The potential toxic effects when testing a new drug is another reason why a substitute for real blood vessels is desperately needed.

Recent advances in stem cell biology, however, are beginning to change things. Induced pluripotent stem cells (iPSCs), which can differentiate into various adult human cell types, allow scientists to grow human tissue in the lab for research. Additionally, iPSC lines produced from patients with genetic diseases offer the ability to investigate specific genetic alterations of interest and their effect in disease onset and progression.

Research has already shown that vascular endothelial cells (iECs) and smooth muscle cells (iSMCs) can be created from human iPSCs. (Endothelial cells form the interior lining of a blood vessel while smooth muscle cells reside within the wall of the blood vessel.) However, because these cells are not derived from an intact blood vessel, they represent what is known as “an immature phenotype,” which means they don’t have all the properties of their naturally formed – or “primary” – counterparts.

The STEM CELLS Translational Medicine study, conducted by researchers from HemoShear Therapeutics, Charlottesville, Va., and the University of Cambridge, was designed to learn whether a “co-culture” of iECs grown on one side of a porous membrane and iSMCs on the other side exposed to blood flow as seen in the healthy and diseased blood vessel would come close to mimicking how primary vascular cells function.

“While many studies demonstrate the utility of iECs and iSMCs for vascular applications, none to date have provided a direct comparison of primary to iPSC-derived EC and SMCs,” said Brian R. Wamhoff, Ph.D., co-founder of HemoShear and a principal investigator in the study. “We did this by simulating normal blood flow through both the co-culture of iPSC-derived cells or primary cells and then again by simulating blood flow through them under advanced inflammatory conditions, such as hardening of the arteries and exposure to drug treatments.”

“While we found that the iPSC-derived cells didn’t perform quite as well as the primary cells under normal blood flow conditions, when it came to advanced inflammatory and drug-related conditions, the iPSCs performed very well,” Dr. Wamhoff said. “Thus, we believe this co-culture may have promise for modeling atherosclerosis or other diseases where no primary cells exist or are challenging to procure.”

“Toxicity of drugs to the blood vessels is a major impediment to the development of new therapies,” said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “This research may result in a viable system for modeling rare vascular diseases and testing new therapeutic approaches.”

###

The full article, “Exposure of iPSC-derived vascular endothelial and smooth muscle cells in co-culture to hemodynamics induces primary vascular cell-like phenotypes,” can be accessed at: http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 35th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 22nd year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14431837.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Imaging shows long-term impact of blast-induced brain injuries in veterans
2. Global Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural etc)- Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
3. Testosterone-regulated genes may affect vaccine-induced immunity
4. Obesity-induced fatty liver disease reversed in mice
5. Malfunction in molecular proofreader prevents repair of UV-induced DNA damage
6. The Pael-R gene does not mediate the changes in rotenone-induced PD model cells
7. New research sets stage for noninvasive monitoring of HIV-induced peripheral neuropathy
8. Ultraviolet light-induced mutation drives many skin cancers, Stanford researchers find
9. Genetics reveals patients susceptible to drug-induced pancreatitis
10. Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released
11. Diet Doc Acknowledges Men’s Health Week By Targeting Weight-Induced Heart Disease and Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: